Greywolf Capital Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Greywolf Capital Management’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-244,686	Closed	-$35.1M	–	9
2016 Q1	$35.1M	Sell	244,686 -33,250	-12%	-$4.72M	6.05%	4
2015 Q4	$43M	Hold	277,936	–	–	7.45%	4
2015 Q3	$39.7M	Hold	277,936	–	–	6.51%	5
2015 Q2	$39.9M	Hold	277,936	–	–	6.03%	6
2015 Q1	$39.2M	Hold	277,936	–	–	10.53%	5
2014 Q4	$41.2M	Hold	277,936	–	–	7.3%	4
2014 Q3	$42.8M	Hold	277,936	–	–	4.76%	4
2014 Q2	$39M	Sell	277,936 -3,751	-1%	-$416K	5.77%	6
2014 Q1	$31.3M	Sell	281,687 -190,448	-40%	-$20.7M	6.29%	4
2013 Q4	$46.7M	Hold	472,135	–	–	10.17%	3
2013 Q3	$35.9M	Buy	472,135 +1,791	+0.4%	+$116K	14.26%	3
2013 Q2	$26.3M	Buy	+470,344	New	+$27.8M	10.45%	5

Other funds holding TARO

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Greywolf Capital Management's TARO Position: Q2 2016 in Review

Greywolf Capital Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2016, closing a stake of 244,686 shares — an estimated $35.1M sold.

Greywolf Capital Management first reported a position in TARO in Q2 2013 and held it in 12 quarters. The position peaked at $46.7M in Q4 2013. 159 funds tracked by Wall St. Rank hold TARO as of Q2 2016.

Greywolf Capital Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2016 after selling out during the quarter.
Greywolf Capital Management sold 244,686 Taro Pharmaceutical Industries Ltd. shares in Q2 2016, an estimated $35.1M.
Greywolf Capital Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2013 and held it in 12 quarters.
Greywolf Capital Management's Taro Pharmaceutical Industries Ltd. position peaked at $46.7M in Q4 2013.
159 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2016.

Based on Greywolf Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.